BioDelivery Sciences International (BioDelivery Sciences International) Short-Term Debt & Capital Lease Obligation : $4.6 Mil (As of Dec. 2021)

View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. BioDelivery Sciences International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $4.6 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. BioDelivery Sciences International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $54.2 Mil.

BioDelivery Sciences International Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for BioDelivery Sciences International's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Short-Term Debt & Capital Lease Obligation Chart

BioDelivery Sciences International Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

4.62

BioDelivery Sciences International Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	-	6.15	3.08	4.62

BioDelivery Sciences International Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

BioDelivery Sciences International Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612

Website

http://www.bdsi.com

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

Executives

James Vollins	officer: See Remarks	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd	director	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	director	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho	officer: See Remarks	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey	director, officer: Chief Executive Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson	director	324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc	director	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha	officer: See Remarks	1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr	director	BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier	director, officer: Chief Executive Officer	C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith	officer: Chief Medical Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612